Market News / Story
Rocket Pharma upgraded at Goldman Sachs on Danon disease therapy
Seeking Alpha ·
Seeking Alpha reports: Rocket Pharmaceuticals rose in afternoon trading on Thursday after Goldman Sachs upgraded the gene therapy developer to Neutral from Sell, citing the latest updates on RP-A501, its experimental therapy for a rare disorder called Danon disease. As part of the updates shared on Wednesday, the New Jersey-based biotech outlined, among other things, a defined path to complete an FDA-aligned pivotal Phase 2 trial for the one-time therapy in Danon disease. “We believe the…